Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/9617
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | McMahon, L P | en |
dc.contributor.author | Dawborn, J K | en |
dc.date.accessioned | 2015-05-15T22:46:50Z | |
dc.date.available | 2015-05-15T22:46:50Z | |
dc.date.issued | 1992-05-16 | en |
dc.identifier.citation | American Journal of Nephrology; 12(3): 162-9 | en |
dc.identifier.govdoc | 1415377 | en |
dc.identifier.other | PUBMED | en |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/9617 | en |
dc.description.abstract | The quality of life of 12 hemodialysis (HD) patients was assessed in a prospective, blinded, cross-over fashion before treatment with recombinant human erythropoietin (r-HuEPO) and at two different levels of hemoglobin (Hb, 9 and 12 g/dl) by means of an interviewer-based questionnaire, the sickness impact profile (SIP). Patients were matched into two groups with no significant difference for age, weight, Hb (6.3 +/- 0.5, mean +/- SEM, group A, vs. 6.4 +/- 0.9 group B), length of hemodialysis or number of years of prior transplantation. SIP was assessed prior to treatment, after reaching the first target Hb (Hb 9 g/dl group A, 12 g/dl group B), after 4 months at that target Hb and after 4 months at the alternative target Hb for each group. For all patients, there was a highly significant improvement in quality of life as assessed by lower SIP scores between the initial and second assessments. This was evident for the physical (8.9 +/- 1.4 vs. 2.8 +/- 1.0; p less than 0.001) and psychosocial (14.9 +/- 3.9 vs. 4.4 +/- 1.1; p less than 0.01) dimensions. Total scores (16.3 +/- 2.4 vs. 5.7 +/- 0.9; p less than 0.001) showed similar changes, reflecting significant improvement in 10 of 12 possible categories between the first two assessments (p less than 0.05 to p less than 0.001). Improved scores were maintained but did not change appreciably after the 2nd assessment. There was no significant difference in any score (category, dimensional or total) obtained after 4 months at Hb 9 g/dl compared to those after the same period at Hb 12 g/dl.(ABSTRACT TRUNCATED AT 250 WORDS) | en |
dc.language.iso | en | en |
dc.subject.other | Anemia.drug therapy.etiology.psychology | en |
dc.subject.other | Attitude to Health | en |
dc.subject.other | Erythropoietin.therapeutic use | en |
dc.subject.other | Hemoglobins.analysis | en |
dc.subject.other | Humans | en |
dc.subject.other | Kidney Failure, Chronic.complications.therapy | en |
dc.subject.other | Middle Aged | en |
dc.subject.other | Prospective Studies | en |
dc.subject.other | Quality of Life | en |
dc.subject.other | Questionnaires | en |
dc.subject.other | Recombinant Proteins.therapeutic use | en |
dc.subject.other | Renal Dialysis.psychology | en |
dc.title | Subjective quality of life assessment in hemodialysis patients at different levels of hemoglobin following use of recombinant human erythropoietin. | en |
dc.type | Journal Article | en |
dc.identifier.journaltitle | American journal of nephrology | en |
dc.identifier.affiliation | Department of Medicine, Austin Hospital, Heidelberg, Victoria, Australia | en |
dc.description.pages | 162-9 | en |
dc.relation.url | https://pubmed.ncbi.nlm.nih.gov/1415377 | en |
dc.type.austin | Journal Article | en |
item.openairetype | Journal Article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | none | - |
item.fulltext | No Fulltext | - |
item.cerifentitytype | Publications | - |
item.languageiso639-1 | en | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.